
Activist Hedge Fund Invests in Novo Nordisk, Maker of Ozempic
Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk, the maker of Ozempic, aiming to influence the appointment of the company's new CEO amid a 50% share price decline driven by disappointing drug trial results and increased competition, despite Novo Nordisk's large market cap and the dominance of its foundation shareholder.
